The U.S. FDA has granted Emergency Use Authorization for CTK Biotech’s ImmuView® COVID-19 Antigen Home Test On December 20th, CTK Biotech obtained the FDA’s Emergency Use Authorization for their ImmuView® COVID-19 Antigen Home Test, a few months after being the first to receive the WHO Emergency Use Listing for their international brand, OnSite® COVID-19 Ag Self Test. The FDA EUA.... Read Full Article >
On July 18th 2022, CTK Biotech’s OnSite® COVID-19 Ag Self Test received WHO Emergency Use Listing for meeting WHO’s quality, safety, and performance requirements. CTK’s COVID-19 Ag Self Test is the first in the market to receive this Pre-Qualification. This milestone accomplishment reflects CTK’s 20-plus years of experience in providing best-in-class products across the globe. Read more about the WHO’s.... Read Full Article >
The Philippines FDA has granted approval of the CTK’s OnSite COVID-19 Ag Self-Test for its high quality and excellent performance.
We’re pleased to announce that CTK’s Onsite COVID-19 Ag Rapid Test has been granted WHO Emergency Use Listing! The OnSite COVID-19 Ag Rapid Test is deemed to meet WHO quality, safety, and performance requirements and is now eligible for relevant procurement agencies and the Member States. To learn more about CTK’s OnSite COVID-19 Ag Rapid Test